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Objectives The primary objective of this study was to determine outcomes in left ventricular assist device (LVAD) patients
older than age 70 years.
Background Food and Drug Administration approval of the HeartMate II (Thoratec Corporation, Pleasanton, California) LVAD
for destination therapy has provided an attractive option for older patients with advanced heart failure.
Methods Fifty-five patients received the HeartMate II LVAD between October 5, 2005, and January 1, 2010, as part of ei-
ther the bridge to transplantation or destination therapy trials at a community hospital. Patients were divided
into 2 age groups: 70 years of age (n  30) and 70 years of age (n  25). Outcome measures including sur-
vival, length of hospital stay, adverse events, and quality of life were compared between the 2 groups.
Results Pre-operatively, all patients were in New York Heart Association functional class IV refractory to maximal medi-
cal therapy. Kaplan-Meier survival for patients 70 years of age (97% at 1 month, 75% at 1 year, and 70% at
2 years) was not statistically different from patients 70 years of age (96% 1 month, 72% at 1 year, and 65%
at 2 years, p  0.806). Average length of hospital stay for the 70-year age group was 24  15 days, similar to
that of the 70-year age group (23  14 days, p  0.805). There were no differences in the incidence of ad-
verse events between the 2 groups. Quality of life and functional status improved significantly in both groups.
Conclusions The LVAD patients 70 years of age have good functional recovery, survival, and quality of life at 2 years. Ad-
vanced age should not be used as an independent contraindication when selecting a patient for LVAD therapy at
experienced centers. (J Am Coll Cardiol 2011;57:2487–95) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.043The utility and application of mechanical circulatory sup-
port (MCS) in patients with advanced heart failure has
significantly progressed since the REMATCH (Random-
ized Evaluation of Mechanical Assistance for the Treatment
of Congestive Heart Failure) trial demonstrated superiority
of the HeartMate I left ventricular assist device (LVAD)
over optimal medical management (1). But these first-
generation pulsatile devices were hindered by limited dura-
bility and high adverse event rates. A new era of MCS was
ushered in by the development and subsequent Food and
From the Sharp Memorial Hospital, San Diego, California. All authors are on the
Speakers’ Bureau for Thoratec Corporation. Sharon A. Hunt, MD, served as Guest
Editor for this paper.Manuscript received June 11, 2010; revised manuscript received January 6, 2011,
accepted January 6, 2011.Drug Administration approval of the HeartMate II (HMII,
Thoratec Corporation, Pleasanton, California) continuous-
flow LVAD (2–5). With its excellent durability, improved
patient survival, decreased incidence of adverse events,
better patient satisfaction, and quality of life, it was shown
to be a superior option to the HeartMate I for both bridge
to transplant patients (2,3) and destination therapy patients
(4). With an increasing population of elderly patients with
advanced heart failure who have limited treatment options,
there are unanswered questions pertaining to whether older
patients can benefit from and are appropriate for this
technology.
Congestive heart failure (CHF) is a common condition
that increases with age. It is estimated that as many as 10%
of people over the age of 70 years may be afflicted, and as
many as 150,000 experience Class IV symptoms (6). Med-
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tion is expensive and offers lim-
ited survival and potential for
functional recovery. Cardiac
transplantation has traditionally
been the gold standard for com-
paring end-stage heart failure
management but with a small
donor pool (approximately 2,000
per year in the United States),
and the pragmatic restriction to
patients under the age of 70
years, it appears that MCS will
become the standard of care for
older, refractory heart failure
patients.
Patients with conditions such
as advanced age, remote history
of cancer, active infections, renal insufficiency, pulmonary
artery hypertension, sensitization, and large body size espe-
cially with a common blood type could potentially be
transplanted but their waiting times are typically prolonged.
Older patients (age 70 years) are the largest potential
group who could benefit from LVAD support, yet advanced
age has consistently been identified as a risk factor for poor
outcome (7–22). These studies have several limitations: 1)
use of proven inferior technology (pulsatile devices); 2)
registry data of LVADs in patients with diverse indications
(i.e., failure to wean from cardiopulmonary bypass, deteri-
oration while awaiting transplantation, and ongoing cardio-
genic shock); and 3) data from a variety of mixed low-
volume and high-volume centers. Therefore, extrapolation
from these earlier results may not accurately reflect the
expected outcome with the newer continuous-flow HMII
device. Hence, the main objective of this study was to
evaluate the outcomes of LVAD patients 70 years of age
from a community hospital with an experienced LVAD
team.
Methods
Patient inclusion criteria. All patients studied met the
linical trial enrollment criteria and the general criteria for
ridge to transplantation/destination therapy LVAD im-
lantation as published by the Centers for Medicare and
edicaid Services (23), including chronic end-stage heart
ailure (New York Heart Association [NYHA] functional
lass IV symptoms failing to respond to optimal medical
anagement, end-stage left ventricular failure for at least 90
ays, and a life expectancy of 2 years), left ventricular
ejection fraction (LVEF) 25%, demonstrated functional
limitation with peak volume of oxygen consumption (VO2)
12 ml/kg/min, continued need for intravenous inotropic
therapy, and an appropriate body size to support LVAD
Abbreviations
and Acronyms
CHF  congestive heart
failure
DTRS  Destination
Therapy Risk Score
JCAHO  Joint Commission
on Accreditation of
Healthcare Organizations
LVAD  left ventricular
assist device
LVEF  left ventricular
ejection fraction
MCS  mechanical
circulatory support
NYHA  New York Heart
Associationimplantation (23). cFacility criteria. Through a National Coverage Determi-
nation issued on October 2003, Medicare began coverage of
the destination therapy indication, and effective March 27,
2007, new facility criteria were established that require
hospitals to receive certification from the Joint Commission
on Accreditation of Healthcare Organizations (JCAHO)
(23). Facilities gaining JCAHO certification are placed on a
list on the CMS website, which is continuously updated
(23,24). During the current study, our facility achieved and
maintained JCAHO certification as a Medicare-approved
LVAD facility.
Pre-operative assessment and clinical optimization. The
criteria adopted for selecting LVAD candidates are summa-
rized in Table 1. All patients underwent comprehensive
evaluation and treatment before LVAD placement that
included clinical assessment of the severity of heart failure,
hemodynamic state, cardiac anatomy, and operative risk.
Inotropic support, diuresis or ultrafiltration, infection sur-
veillance/treatment, and nutritional assistance were pro-
vided when needed. On the basis of response to treatment,
it was determined whether the patient should continue
medical treatment or hospice, high-risk surgical repair with
LVAD standby, or become a candidate for destination
LVAD therapy or transplantation. For nonresponders, the
decision was whether they were appropriate LVAD candi-
dates or too sick for support. Noncardiac considerations
such as history of chronic or life-limiting illnesses, mental
status, nutritional status, expectations (quality of life versus
duration of life), and psychosocial and age-related consid-
erations were assessed.
NEUROLOGICAL ASSESSMENT. A neurological evaluation
was ordered if necessary to rule out degenerative central
nervous system diseases and dementia. Because it is imper-
ative that candidates for LVAD therapy demonstrate the
ability to operate the device safely, we assessed for stroke,
psychiatric disorders, mental retardation, substance abuse,
and other factors that could potentially impact compliance
with medical regimen and clinic visit follow-ups (25).
RENAL ASSESSMENT. Patient’s baseline renal function was
eviewed because poor baseline renal function is associated
ith worse outcomes after LVAD implantation (26–28).
his review included assessment of renal parameters as well
s pre-operative diuretics use and aggressive treatment of
eart failure (inotropic support, ultrafiltration, or dialysis).
NUTRITIONAL ASSESSMENT. For each patient, a compre-
ensive assessment was made to define the degree of
alnutrition and estimate the severity of illness. We typi-
ally use the Subjective Global Assessment and Severity of
llness scales to determine the level of malnutrition and to
etermine when to start nutritional support (29).
PSYCHOSOCIAL ASSESSMENT. When evaluating the pa-
ient’s social support network, we reviewed the presence and
ge of the caregiver, such as a spouse or family member, who
ould be available in case of device malfunction. We
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June 21, 2011:2487–95 HeartMate II in Patients Older Than 70 Years of Agereviewed a plan of care for discharge that would ensure that
the home environment was safe and allow the patient to
receive adequate post-operative care. We looked at patients’
ability to care for themselves, including eyesight, hearing,
dexterity, and evidence of poor dentition, as well as any
history of noncompliance with medical regimens. Social
workers reviewed the availability of patient-related commu-
nity resources. If significant questions were unanswered,
then a trained home health nurse visited the patient’s home
to complete the assessment.
INFORMED CONSENT. All patients received the information
necessary to assist them in giving appropriate informed
consent for the procedure. The patient and significant
others signed a healthcare contract delineating the expecta-
tions for after care.
POST-OPERATIVE MANAGEMENT. Prevention of right-side
eart failure was implemented in all patients, and included
he routine use of inhaled nitric oxide, biventricular pacing
hen necessary, and the use of inotropic drugs such as
soproterenol, dopamine, and milrinone in the immediate
ost-operative period. Patients with impaired right ventric-
lar function were given sildenafil routinely, and the inhaled
itric oxide was weaned within 24 to 48 h in most cases.
ursing care in the cardiac step-down unit focused on
trengthening, self-care, and education about LVAD
anagement.
atient population. Fifty-five consecutive patients receiv-
ng HMII LVADs included in the bridge to transplantation
r destination therapy clinical trials from October 2005 to
anuary 2010 at a small community hospital with extensive
Criteria for Selecting Patients as LVAD CandidatesTable 1 Criteria for Selecting Patients as LVAD Candidates
Characteristics of Patients Selected for
LVAD Therapy
High-Risk LVAD Pa
Absolute Contra
Intolerable congestive heart failure symptoms
and/or lifestyle limitations despite maximal
medical/surgical therapies
Severe chronic obstructive
Meets national standardized inclusion criteria History of stroke with wors
defect secondary to con
Adequate mental, psychological, social, and
financial support to comply with the
complex LVAD management protocols
Primary right-side heart fa
hypertrophic myopathy,
right ventricular dysplasi
constrictive/restrictive d
A strong desire to have an LVAD implanted
held by both the patient and his/her
significant other caregivers.
Fixed pulmonary artery hy
Active infections
Hepatic fibrosis or cirrhosi
Blood dyscrasias (heparin-
thrombocytopenia, hype
current 2B3A drug use)
Renal failure including chr
dependence
Patient or significant othe
regarding the LVAD imp
LVAD  left ventricular assist device.CS experience were evaluated. Patients were divided into lgroups on the basis of age at the time of implant: patients
70 years of age (n  25), and patients 70 years of age
n  30). During the study period, 329 patients were
eferred for consideration of LVAD or transplantation, and
f those, 15% (49 of 329) were age 70 years or older. The
ajority, 61% (30 of 49), of patients 70 years of age or older
ccepted and underwent HMII implant. Four patients (8%)
ere considered to be good candidates but refused our
ecommendation, 16% (8 of 49) were too well, whereas only
% (4 of 49) were too ill. One patient underwent traditional
eart surgery (coronary artery bypass graft) and mitral valve
epair, 1 patient had insufficient psychosocial support, and 1
atient was lost to follow-up and the precise reason for
efusal was unknown. In the younger than 70 years of age
opulation, 46% (103 of 280) either received a HMII or
nderwent transplant, 14% (40 of 280) were too well, 5%
13 of 280) underwent a traditional cardiac operation, 4%
10 of 280) were too ill, 13% (37 of 280) were not
onsidered to be good LVAD candidates, 8% (24 of 280)
ailed to keep their appointment, and 3% (9 of 280) refused
o accept our advice for LVAD or transplant. Only patients
mplanted as part of the HMII trial were studied, as
omplete datasets were available only for these patients.
utcomes. The groups were compared with regard to
re-operative patient characteristics and outcome measures,
ncluding Kaplan-Meier survival, prevalence and incidence
f adverse events, quality of life metrics (Kansas City
ardiomyopathy Questionnaire Clinical Summary Scores
nd Overall Summary Scores, Minnesota Living With
eart Failure questionnaire), and functional status (6-min
alk distance, NYHA functional class, and patient activity
ut Not
tions
Contraindications
to LVAD Support
nary disease Patient refusal
neurocognitive
e heart failure
Insufficient significant other support, home environment,
or financial resources
.e.,
hmogenic
st-transplant
Irreversible neurocognitive defects that preclude routine
LVAD care
sion Ongoing cardiogenic shock refractory to all resuscitation
measures including peripheral cardiopulmonary
bypass resuscitation
End-stage pulmonary disease out of proportion to
congestive heart failure
Fungemia
d
ulable states,
Ongoing drug or alcohol addiction or recent history of
noncompliance to medical therapy
ialysis
valencetient B
indica
pulmo
ened
gestiv
ilure (i
arrhyt
a, or po
isease
perten
s
induce
rcoag
onic d
r ambi
lantevels with the Metabolic Equivalent Task Score) (5).
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HeartMate II in Patients Older Than 70 Years of Age June 21, 2011:2487–95Statistical analysis. Statistical analyses except for Poisson
regression were done using SYSTAT (Cranes Software,
Chicago, Illinois). Poisson regression was performed using
SAS (SAS Institute, Cary, North Carolina). Differences
between groups of independent, normally distributed, con-
tinuous variables were evaluated using the t test. Variables
that were not normally distributed were evaluated using the
Mann-Whitney U test. Normality was checked using the
nderson-Darling test. Differences in categorical variables
ere evaluated using the Fisher exact test. Statistical com-
arisons were 2-sided, and the level of significance was set
t p  0.05. Survival analysis was performed using the
Kaplan-Meier method, with patients censored for trans-
plantation, recovery of native heart function with device
removal, or withdrawal from the study. Comparison of
survival between the 2 groups was performed using the
log-rank test. Adverse events are presented as both percent-
ages of patients and event rates (events per patient-year).
Comparisons of adverse event rates between the 2 groups
were performed using a Poisson regression model (Mantel-
Haenszel), with the total duration of support as the expo-
sure time and total number of events as the response
variable. Quality of life comparisons were performed using
linear mixed-effects modeling (MIXED subroutine in
SYSTAT). The predictor variables were age group, time
group (baseline, 1 month, 3 months, and 6 months), and age
group by time group. Eight patients (4 in each group) had
a previous pulsatile flow LVAD that was replaced with an
HMII LVAD. Duration of support and survival for these
patients was evaluated from the date of the first LVAD
implant. Only adverse events that were observed when on
the HMII device were included.
Results
Baseline patient characteristics. The age distribution of
LVAD patients in this study shows most were between the
ages of 60 and 80 years (Fig. 1) Baseline characteristics were
similar between groups except for age, nutritional status
(pre-albumin), use of angiotensin-converting enzyme inhib-
Figure 1 Patient Age Distribution
Age distribution of patients evaluated in this study.oitors, and ventilator support (Table 2). There was a ten-
dency for a higher prevalence of ischemic etiologies and
prior cardiac resynchronization therapy in the 70-year age
group than in the 70-year age group, but these differences
were not statistically significant. All patients were in NYHA
functional class IV before LVAD implant. There was no
difference in the mean Lietz-Miller destination therapy risk
score (30) between the 70-year age group (10.5  6.3)
and 70-year age group (8.3  5.8, p  0.205), nor in the
percentage of patients with high/very high risk scores or low
risk scores.
Operative procedures. Associated concomitant operative
procedures are listed in Table 3. Four patients in each group
had a prior HeartMate XVE exchanged for an HMII.
There were no statistically significant differences between
the 2 groups in the number of patients undergoing mitral
valve repair/replacement, tricuspid valve repair/replacement,
aortic valve patch closure, patent foramen ovale closure, or
any other concomitant procedures performed at the time of
surgery. One 70-year-old patient had a right ventricular
assist device (Biomedicus pump, Medtronic, Minneapolis,
Minnesota), which was removed after 2 days, compared
with none in the 70-year age group. Cardiopulmonary
bypass times were similar between the 70-year age group
and 70-year age group (80  32 min vs. 83  41 min, p
0.760).
uration of support. Patients in the 70-year age group
ere supported for an average of 678  676 days (median
15 days, range 8 days to 8 years), and patients in the
70-year age group were supported for 539  475 days
median 482 days, range 19 days to 5.6 years; p  0.630).
hirteen patients in the70-year age group were supported
ith an LVAD for 1 year, including 9 patients for 2
ears, 4 patients for 3 years, 3 patients for 4 years, and
he longest, for 8 years. Comparatively, 16 patients in the
70-year age group were supported for 1 year, including
patients for 2 years, 4 patients for 3 years, 2 patients
or 4 years, and the longest, for 5.6 years.
utcomes. The Kaplan-Meier survival for both groups
ere comparable (log-rank p  0.806) (Fig. 2A). Survival
ates for the70-year age group versus70-year age group
ere similar at 30 days (96% vs. 97%), 6 months (88% vs.
3%), 1 year (72% vs. 75%), and 2 years (65% vs. 70%).
urvival rates for patients receiving the HMII as their initial
evice, after excluding those who received it as an exchange
or the XVE, were also similar (p  0.898) at 1 year (65%
s. 70%) and 2 years (65% vs. 70%) (Fig. 2B). In the
70-year age group, 6 patients (24%) died, 2 patients (8%)
ere transplanted, 1 patient (4%) recovered cardiac function
nd had the LVAD removed, and 16 patients (64%) were
till receiving ongoing LVAD support (3 for1 year, 13 for
1 year) at 1 year. Similarly, in the 70-year age group, 7
atients (23%) died, none underwent transplant or recov-
red cardiac function, and 23 (77%) were still receiving
ngoing LVAD support (7 for 1 year, 16 for 1 year) at
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June 21, 2011:2487–95 HeartMate II in Patients Older Than 70 Years of Age1 year. No significant differences in the causes of death were
observed between the 2 groups (Table 4).
Length of stay and hospital course. The average length of
stay in the hospital was similar for the 70- and 70-year
ge groups (23  14 days vs. 24  15 days, respectively;
Comparison of Baseline Characteristics BetweeTable 2 Comparison of Baseline Characteris
Parameter <70 Yrs (n
Patients enrolled 25
Age, yrs (minimum–maximum) 56.7 14.3
Ischemic 15
BSA, m2 1.98 0
Weight, kg 83 1
LVEF, % 21 9
CI, l/min/m2 1.95 0
PCWP, mm Hg 27 9
Systolic BP, mm Hg 104 1
Creatinine, mg/dl 1.76 1
BUN, mg/dl 34.3 2
ALT, U/l 81 2
AST, U/l 98 1
Total bilirubin, mg/dl 1.08 0
Albumin, g/dl 3.55 0
Pre-albumin, mg/dl 16 7
Na, mmol/l 135.3 5
Beta-blockers 6
ACE inhibitors 2
Intravenous inotrope agents 17
Single inotrope 10
More than 1 inotrope 7
CRT 9
ICD 16
Ventilator support 5
IABP 3
DTRS 10.5 6
DTRS low risk 10
DTRS high/very high risk 5
Body surface area (BSA), cardiac index (CI), pulmonary capillary wedg
Destination Therapy Risk Score (DTRS) were normally distributed and e
ejection fraction (LVEF), creatinine, blood urea nitrogen (BUN), alanine a
sodium (Na), were evaluated using the nonparametric Mann-Whitney
ACE  angiotensin-converting enzyme; CRT  cardiac resynchro
cardioverter-defibrillator.
Associated Operative ProceduresTable 3 Associated Operative Procedures
Procedure
Age Group
p Value
<70 Yrs
(n  25)
>70 Yrs
(n  30)
HeartMate XVE replaced with HMII 4 (16%) 4 (13%) 1.000
Mitral valve repair/replacement 8 (32%) 11 (37%) 0.781
Tricuspid valve repair/replacement 5 (20%) 5 (17%) 1.000
Aortic valve patch closure 6 (24%) 7 (23%) 1.000
Patent foramen ovale closure 3 (12%) 2 (7%) 0.650
Other procedures 5 (20%) 7 (23%) 1.000
Other procedures include cardiopulmonary support removal, coronary artery bypass, hernia repair,
right ventricle/left ventricular pacing lead placement, bronchoscopy, left atrial appendage ligation,H
and cryoablation.
HMII  HeartMate II. 0.805). Some patients stayed longer in the intensive
are unit, primarily for respiratory care and right ventricular
eaning of intravenous inotropic medications. Non–device-
elated rehospitalizations included infirmaries related to
rthopedic surgery, cholesystectomy, transurethral resection
f the prostate, and Clostridium difficile infection.
uality of life and functional status. Outcomes associated
ith the quality of life and functional status are shown in Table
. The percentage of patients in NYHA functional class I or II
mproved from 0% at baseline to 100% (70-year age group)
nd 89% (70-year age group) at 6 months. There were
tatistically significant improvements in the 6-min walk dis-
ance from baseline (for those able to walk) to 6 months for the
70-year age group (256 to 275 m) and the 70-year age
roup (233 to 295 m). There were also significant improve-
ents by approximately 36 (70-year age group) and 42
oints (70-year age group) at 6 months in heart failure-
elated quality of life metrics using theMinnesota LivingWith
2 GroupsBetween the 2 Groups
Age Group
p Value>70 Yrs (n  30)
30 (55%) —
) 76.3 3.9 (70–87) 0.001
24 (80%) 0.140
1.95 0.19 0.671
79 15 0.276
20 6 0.651
1.67 0.49 0.139
27 9 0.824
108 15 0.438
1.47 0.61 0.420
32.8 15.4 0.939
62 123 0.205
44 48 0.141
0.99 0.53 0.932
3.76 0.52 0.137
21 6 0.030
136.9 4.6 0.297
13 (43%) 0.163
13 (43%) 0.005
18 (60%) 0.585
14 (47%) 0.785
4 (13%) 0.198
19 (63%) 0.06
25 (83%) 0.128
0 (0%) 0.015
0 (0%) 0.088
8.3 5.8 0.205
15 (50%) 0.588
4 (13%) 0.716
ure (PCWP), systolic blood pressure (BP), albumin, pre-albumin, and
d using the t test. The remaining continuous variables, left ventricular
ansferase (ALT), aspartate aminotransferase (AST), total bilirubin, and
n therapy; IABP  intra-aortic balloon pump; ICD  implantablen thetics
 25)
(45%)
(16–69
(60%)
.21
5
.72
9
.17
0.1
09
65
.78
.52
.5
(24%)
(8%)
(68%)
(40%)
(28%)
(36%)
(64%)
(20%)
(12%)
.3
(40%)
(20%)
e press
valuate
minotr
U test.eart Failure Questionnaire. Similarly, there was a 32-point
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HeartMate II in Patients Older Than 70 Years of Age June 21, 2011:2487–95increase (70-year age group) and a 42-point increase (70-
ear age group) in mean values of the Kansas City Cardiomy-
pathy Questionnaire overall summary score (Table 5). Patient
ctivity levels significantly increased in this period as well. The
ercent of patients achieving a Metabolic Equivalent Task
core of 3 (moderate activity) or higher improved from 12% at
aseline to 63% at 6 months (70-year age group) compared
ith 7% to 52% (70-year age group). Overall, there was no
ifference in any of the quality of life or functional status
Figure 2 Kaplan-Meier Survival Analysis
(A) Survival of patients, including those who had a HeartMate XVE replaced
with a HeartMate II (HMII). (B) Survival of patients with the HMII as their first
device, excluding patients who had a HeartMate XVE replaced with an HMII.
Red lines indicate age 70 years; blue lines indicate age 70 years.etrics between the 2 groups.dverse events. The incidence of adverse events (Table 6)
as similar between the70-year and70-year age groups
or bleeding requiring packed red blood cells (0.33 vs. 42
vents per patient-year, p  0.591) and requiring surgery
0.15 vs. 0.11, p  0.583), device-related infection (0.15 vs.
.13 events per patient-year, p  0.813), and incidence of
emorrhagic stroke (0.03 vs. 0.05 events per patient-year,
 0.557) and ischemic stroke (0.03 vs. 0.03 events per
atient-year, p  0.985).
iscussion
his study shows that excellent results can be obtained with
VAD support as destination therapy for advanced heart
ailure patients over the age of 70 years. We believe that this
ype of mechanical support should be considered as an
ttractive option for select patients refractory to maximal
edical therapy, and that age should not be an absolute
ontraindication to LVAD support. The results also indi-
ate that very good results can be achieved in a community
ospital setting with a focused effort from a dedicated team.
Even though heart failure is a major public health
roblem affecting 5 million Americans, with an estimated
50,000 in NYHA functional class IV heart failure, and
arly LVAD technology was proven superior to medical
herapy, there was only a modest increase in the number of
atients receiving LVADs. Lietz et al. (15) reported that
nly 451 patients underwent destination therapy device
lacement with pulsatile LVADs during the first 5 years
fter the REMATCH trial, and destination therapy ac-
ounted for only 17% of the devices implanted. Also, with
he incidence of NYHA functional class IV heart failure
ncreasing with age, one would expect national LVAD
Causes of DeathTable 4 Causes of Death
Age Group
p Value<70 Yrs >70 Yrs
Causes of death 12 months (n  6/25; 24%) (n  7/30; 23%)
Sepsis 1 (4%) 1 (3%) 1.000
Respiratory failure 2 (8%) 1 (3%) 0.586
Multiorgan failure 0 (0%) 1 (3%) 1.000
Ischemic stroke 1 (4%) 0 (0%) 0.455
Hemorrhagic stroke 0 (0%) 1 (3%) 1.000
Device thrombosis 1 (4%) 0 (0%) 0.455
Patient disconnected power 1 (4%) 0 (0%) 0.455
Cancer 0 (0%) 1 (3%) 1.000
Withdrawal of support 0 (0%) 1 (3%) 1.000
Unknown 0 (0%) 1 (3%) 1.000
Causes of death 12 months (n  2/25; 8%) (n  3/30; 10%)
Anoxic brain injury 0 (0%) 1 (3%) 1.000
Cardiomyopathy 1 (4%) 0 (0%) 0.455
Sepsis 1 (4%) 0 (0%) 0.455
Unknown 0 (0%) 1 (3%) 1.000
Respiratory failure 0 (0%) 1 (3%) 1.000Values are n (%) of implanted patients.
Functional Capacity and Quality of LifeTable 5 Functional Capacity and Quality of Life
Age <70 Yrs Age >70 Yrs
Baseline 1 Month 3 Months 6 Months p Value* Baseline 1 Month 3 Months 6 Months p Value* p Value†
NYHA functional class
Patients tested at interval 24 21 21 20 29 26 20 19
Class I/II 0 (0%) 10 (48%) 18 (86%) 20 (100%) 0.001 0 (0%) 11 (42%) 18 (90%) 17 (89%) 0.001 0.351
6-min walk test
Patients tested at interval 6 14 18 17 15 17 17 15
Distance walked (m) 256 96 188 113 354 162 275 135 0.001 233 100 162 114 256 100 295 97 0.004 0.221
Minnesota Living With Heart Failure Questionnaire
Patients tested at interval 18 20 22 20 26 23 20 17
Score 73 33 65 26 41 23 37 26 0.001 65 21 50 23 46 28 23 19 0.001 0.072
Kansas City Cardiomyopathy Questionnaire
Patients tested at interval 18 20 22 20 25 23 22 18
Overall summary score 32 28 40 27 61 26 64 26 0.001 33 18 42 23 60 24 75 24 0.001 0.587
Clinical summary score 41 29 47 26 67 22 70 25 0.001 42 19 45 22 63 20 77 21 0.001 0.881
Patient activity levels (METs)
Patients tested at interval 25 23 23 19 30 27 23 20
% METS 3 or higher 3 (12%) 4 (17%) 15 (65%) 12 (63%) 0.001 2 (7%) 4 (15%) 12 (52%) 17 (85%) 0.001 0.205
*The p value is for changes over time. †The p value is for differences between older and younger patients.
METS  Metabolic Equivalent Task Score; NYHA  New York Heart Association.
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that has not been the case.
The main reason for this discrepancy is that the pulsatile
devices had poor reliability and significant adverse events
rates. Although there was a survival advantage demonstrated
in the REMATCH study, the outcomes led many to
question whether the increased length of life was worth the
expense to both the patients and the health care system.
Another factor is age, which has consistently been identified
in multiple studies as a risk factor for decreased survival and
increased adverse events after LVAD placement (7–22).
However, these previous studies have significant limitations.
First, the impact of comorbidities and the presence of
irreversible cardiogenic shock were not controlled. Second,
many studies used a mixture of devices in their review that
may confound the overall analysis, and some of the data
come from registries for which the robustness of the data is
suspect. Given these shortcomings, we do not have sufficient
published data on continuous-flow devices implanted at
experienced centers to conclude that advanced age should be
a contraindication to LVAD therapy.
One important positive factor in the use of LVAD
therapy for older patients is that they are very appreciative of
the improved quality of life afforded by the LVAD.
Whereas younger patients want to live longer, older patients
want to live better. Older patients are also typically more
compliant with medications and instructions from caregiv-
ers, and do not have increased adverse events just because of
their age. Selecting the right older patient is critical. Older
patients can have more associated illnesses and other con-
comitant problems with the native heart that need to be
considered. Rigorous assessment and optimization of pre-
operative status should be undertaken, including neurolog-
Adverse EventsTable 6 Adverse Events
Adverse Events
Age <70 Yrs (n  25), 38.8 P
Incidence Patients
(%)
Ev
(Events
Bleeding requiring PRBC 7 (28%)
Bleeding requiring re-exploration 5 (20%)
Infection
Local nondevice related 12 (48%)
Sepsis 6 (24%)
Device-related 5 (20%)
Cardiac arrhythmias 8 (32%)
Cardioversion/defibrillation
Renal failure 1 (4%)
Right-side heart failure 1 (4%)
RVAD 0 (0%)
Ischemic stroke 1 (4%)
Hemorrhagic stroke 1 (4%)
Other neurological events
(TIA, seizures, confusion, and so on)
4 (16%)
Hemolysis 0 (0%)
PRBC  packed red blood cells; RVAD  right ventricular assist device; TIA  transient ischemicical, nutritional, psychosocial, and renal assessments. Opti-mal outcomes in LVAD patients can be achieved with a
dedicated LVAD team organized and charged with implan-
tation, early post-operative management, and outpatient
management, as outlined in a recent publication on clinical
management of continuous flow LVADs (31). Our study
shows that if such practices are adopted, then good out-
comes can be achieved.
Center experience has been shown to play an important
role in determining outcomes with LVAD therapy (15).
Our implant techniques, patient selection, and management
protocols are constantly improving. This study demon-
strates that destination therapy LVAD therapy can safely be
delivered to an older patient population in a small commu-
nity hospital with an experienced team. In fact, our survival
rates are higher and the rates of adverse events were lower in
both groups when compared with the results of the multi-
center HMII trials (2–4). Similar outcomes can be achieved
in other hospital settings as well.
Patient selection is an important question to be answered
if these results are to be duplicated in other centers. The
majority of referred patients age 70 years or older (61%)
were considered to be good candidates and successfully
received their LVADs. From epidemiologic data, we know
that the number of elderly patients with terminal heart
failure is much larger, so one must assume that only a very
small and select sample of this population is being referred.
We have no way to evaluate why physicians do not refer
some patients, but we can say that on 3 occasions patients
were self-referred from hospice and successfully implanted,
implying that many patients who are acceptable candidates
are not referred.
Study limitations. The main limitation of this study is that
observations were based on small numbers of patients from
t-Yrs Age >70 Yrs (n  30), 37.7 Patient-Yrs
p Value
te
tient-Yr)
Incidence Patients
(%)
Event Rate
(Events per Patient-Yr)
9 (30%) 0.42 0.591
3 (10%) 0.11 0.583
14 (47%) 0.72 0.853
6 (20%) 0.19 0.854
5 (17%) 0.13 0.813
10 (33%) 0.29 0.802
1 (3%) 0.03 0.984
1 (3%) 0.03 0.984
1 (3%) 0.03 0.317
1 (3%) 0.03 0.984
2 (7%) 0.05 0.557
3 (10%) 0.08 0.746
0 (0%) 0.00 —atien
ent Ra
per Pa
0.33
0.15
0.67
0.21
0.15
0.26
0.03
0.03
0.00
0.03
0.03
0.10
0.00a single center participating in a multicenter clinical trial.
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evaluation was retrospective, and therefore the numbers are
less reliable for total patients referred and identifying the
precise reasons for refusal.
Conclusions
Advanced heart failure patients receiving an HMII LVAD
who were older than 70 years had outcomes similar to those
of patients younger than 70 years. Older patients had
acceptable length of hospital stays, adverse events, and
functional recovery. Advanced age should not be used as an
independent contraindication when selecting a patient for
LVAD therapy. As this technology continues to improve,
increasing numbers of older patients will seek centers for
destination therapy. Analysis of the referral data suggests
that more patients should be referred for LVAD evaluation
at an experienced center, because good outcomes can be
achieved in this patient cohort.
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